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Abstract
Background: Despite the use of combination antiretroviral therapy, HIV associated
neurocognitive impairment (NCI) persists in HIV seropositive persons, albeit in milder forms than
before therapy was available. Nevertheless, the relationship between NCI and health-related
quality of life (HRQoL) is not well known.
Method: Baseline data from the CHARTER study was used to investigate the association
between NCI and HRQoL. Factor analysis was employed to summarize the 35-item Medical
Outcome Survey questionnaire into physical and mental HRQoL scores. General linear models
were employed to investigate the association between NCI, as measured by global deficit scores
(GDS), and HRQoL, and to control for confounding.
Results: A total of 1,340 HIV participants were analyzed, including 35.6% NCI, 77.2% males,
70.5% unemployed, and 42.2% depressed. The mean (standard deviation) mental HRQoL scores
(lower scores are worse) for impaired and unimpaired participants were 64.0 (18.4) and 67.9
(18.6) and mean physical HRQoL scores for impaired and unimpaired participants were 60.3
(24.7) and 65.1 (25.9), respectively. There was an inverse association between NCI and mental
HRQoL in unadjusted [-4.38 (-6.70 to -2.06)] and adjusted analysis [-2.56 (-4.83 to -0.30)],
controlling for unemployment and current psychotropic medication use. The association between
NCI and physical HRQoL was significant in unadjusted analysis [-4.62 (-7.45 to -1.78)] but not in
adjusted analysis [2.20 (-4.81 to 0.40)], controlling for unemployment, CD4 nadir and positive
opiate test results and other covariates.
Conclusion. The inverse association between NCI and HRQoL was confounded mainly by
employment and mediated by depression. Interventions aimed at the comprehensive treatment
of HIV patients should include the management of depression and maintenance of employment.
Key Words: Neurocognitive impairment. Quality of life. Medical outcome survey questionnaire.
Human Immunodeficiency Virus (HIV). Global deficit scores (GDS).
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Introduction
HIV-1 enters the brain early during infection [1] when infected monocytes, lymphocytes [2] or viral
particles cross the blood brain barrier (BBB) [3]. The virus can then infected macrophages and
microglia in the central nervous system (CNS) and cause immune activation and indirect damage
to neurons [3, 4].
HIV-1 replication and continuous immune activation in the CNS causes alterations in brain
structure, the degeneration of brain cells and alterations in brain gray and white matter volume,
and brain abnormalities [5]. Persistent immune activation can result in immune dysfunction,
neuro-inflammation, and injury to synapses and dendrites [1, 6, 7]. Injury to synapses affects the
functioning of neurotransmitters, the transmission of electrical impulses from one neuron to the
other, and may contribute to neurocognitive impairment, neuropathy and decline in health-related
quality of life [1, 8, 9]. Although the introduction of combination antiretroviral therapy (cART) in
the late 1990s has resulted in decreased HIV related mortality, morbidity and HIV related
dementia, mild to asymptomatic forms of HIV associated neurological disorders (HAND) remain
a problem [11]. HAND may be due to the direct neurotoxic effects of combination antiretroviral
therapy (cART) that cause neuronal damage or dysfunction [1]. Additionally, once macrophages
and microglial cells are infected, they serve as reservoirs for the virus in the brain where it can
continue to replicate, evading HIV-drugs with limited CNS penetration [12].
HIV in the CNS and the neurotoxic effect of cART are not the only risk factors for cognitive
impairment and the associated impact on quality of life of HIV patients. Studies have shown that
substance abuse and drug use aggravate the deleterious effect of HIV on brain metabolites [13],
lead to neuronal injury [14] and negatively affect neuropsychological functioning [15]. Hepatitis C
virus coinfection is associated with cognitive impairment and domain specific dysfunction [16, 17].
HIV positive individuals with a syphilis co-infection or history of prior syphilis infection are at
increased risk of neurocognitive impairment and neuropsychological dysfunction compared to HIV
negative individuals with no history of syphilis [18, 19]. Cardiovascular risk factors associated with
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aging can influence cognitive dysfunction particularly slowing of psychomotor speed and cognitive
performance [2]. Coronary heart disease increases the likelihood of developing cognitive
impairment [20, 21]. Depression, hypertension, physical inactivity, diabetes, obesity,
hyperlipidemia, and smoking are strong risk factors for dementia [22]. A higher body mass index
(BMI) is associated with cognitive dysfunction in healthy individuals [23, 24], alterations in cortical
gray and white matter volumes [25] and slower processing speed [26]. Dyslipidemia caused by
high LDL cholesterol and triglyceride concentrations in the blood is associated with sensory
neuropathy and cognitive impairment in people infected with HIV [27]. Psychiatric disorders have
a deleterious effect on cognitive function [28-31] and psychotropic drug use may negatively affect
memory, attention, psychomotor performance and cognitive function [32]. Age has effect on brain
gray and white matter volume and results in degeneration of brain cells [33]. Additionally, genetic
factors such as polymorphisms in host immune response genes have been associated with CNS
inflammation and the effect of antiretroviral therapy on viral replication, suppression and sideeffects on the brain [34].
The deleterious effect of HIV infection and associated comorbidities on quality of life of
HIV participants are well documented [19, 28, 35-39]. Nevertheless, few studies have investigated
the relationship between HIV-associated neurocognitive impairment (NCI) and health-related
quality of life or the neurotoxic effects of cART on health-related quality of life in HIV participants.
We analyzed the Central Nervous System HIV Antiretroviral Therapy Effects Research
(CHARTER) study to investigate the relationship between HIV-associated NCI and health-related
quality of life (HRQoL). An understanding of the predictors of HRQoL of HIV participants with NCI
can contribute to the knowledge based necessary to inform comprehensive HIV management.

Study Objectives
The main objective of this study was to examine the relationship between
neurocognitive impairment, as measured by global deficit scores (GDS), and HRQoL using
baseline data from the CHARTER study. We hypothesized that HIV-associated (NCI) is
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associated with HRQoL and there is a significant difference in HRQoL between impaired and
unimpaired participants. A secondary objective of this analysis was to determine whether the
Medical Outcome Survey (MOS) questionnaire can be summarized into physical and mental
health summary scores using factor analysis.

Methods
Data Source and Participants
We analyzed data from the CHARTER study, a prospective, observational study
conducted from 2004 to 2015 in three phases [18, 42]. The primary aim of the CHARTER study
was “to determine how central and peripheral nervous system complications of HIV are affected
by different histories and regimens of antiretroviral therapy” (https://charternntc.org/). The study
design is described in detail in [42, 44]. Baseline data collected from 2004 to 2007 at the time of
recruitment was analyzed. All participants for this study were HIV infected individuals recruited
from six university research clinics in the United States [42, 44]. The Institutional Review Board
of each participating Institution reviewed and approved the study [44].
The CHARTER study used a volunteer sample. A total of 2,016 HIV participants that
attended a clinic at the participating university centers were screened at baseline and invited to
participate in the study, with minimal exclusion criteria [42, 43]. Participants were excluded from
the study only if they declined to participate or if they could not complete the assessment at the
time of evaluation [42, 44]. Of the participants screened, 40 (2.0%) were not asked to continue
while 366 (18.2%) declined to participate. Cross sectional baseline data were collected from 1,610
HIV infected participants from six centers. For the current study, 1,587 participants who had
complete data on HRQoL were included in the factor analysis. Participants with missing data on
study variables and those with confounding comorbidities were excluded from the final analysis
(Figure 1). Confounding comorbidities were determined based on expert ratings of the comorbidity
status of participants in all six centers using standard guidelines [44]. All participants were
classified as having incidental, contributing or confounding comorbidities. “Confounding
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conditions that could fully explain significant neuropsychological impairment and currently
observed problems with everyday functioning” [44] preclude the attribution of NCI solely to the
effects of HIV on the brain so persons with confounding comorbidities were removed from the
analysis [44].
Dependent and Independent Variables
HRQoL was measured by the standardized 35-item MOS questionnaire, which is based
on patients’ self-reports of their subjective wellbeing [46]. The main outcome variables were
physical and mental HRQoL summary scores derived from the questionnaire. The 35-item
questionnaire was summarized into ten scales: pain, physical functioning, social functioning,
mental health, energy or fatigue, health distress, cognitive functioning, general health, role
functioning and quality of life scales. Previous studies have shown that these scales can be
reduced into distinct physical and mental health summary scores for a sample of HIV participants
[47]. Following procedures in [47], the 35-item questionnaire was reduced into physical and
mental HRQoL summary scores, which served as the main outcome variables. The main
independent variable was HIV-associated NCI as measured by GDS. Data to compute cognitive
impairment were collected using a comprehensive set of neuropsychological tests covering seven
cognitive domains [18]. Standard methods were used to compute cognitive impairment using GDS
described elsewhere [44,45].
Statistical Analysis
Exploratory and confirmatory factor analysis was conducted to reduce the 35-item MOS
questionnaire to physical and mental health dimensions. Factor analysis was based on a
complete case analysis of 1,587 participants using SAS version 9.4, after deleting 23 (1.4%)
cases with missing data. Data reduction to compute summary scores for the MOS questionnaire
followed a three-step process. In the first step, eleven of the 35 items of the MOS questionnaire
were reverse coded to ensure that higher scores reflect a more favorable health status. The 35
items were then summarized into eleven scales by adding questionnaire items designed to
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measure common constructs. The scales were; pain (2 items), physical functioning (6 items), role
functioning (2 items), social functioning (1 item), mental health (5 items), energy or fatigue (4
items), health distress (4 items), cognitive functioning (4 items), general health perception (5
items), quality of life (1 item) and health transition (1 item). The scales were transformed to 0 to
100 scores with 100 representing best health status [47]. In the second step, we performed
exploratory factor analysis on a subsample of 794 participants representing half of the full dataset
randomly selected from the total sample using the SAS PROC SURVEYSELECT procedure. The
exploratory factor analysis procedure used squared multiple correlations as prior communality
estimates. Two factors were extracted by the principal factor method followed by a promax
rotation [48]. Health transition did not load on any factor, so it was not included in the confirmatory
factor analysis. In the third stage, the extracted factors were validated using confirmatory factor
analysis applied to the full dataset of 1,587 participants. A measurement model that describes the
relationship between the 2 latent factors and the 10 scales was developed and confirmatory factor
analysis was conducted to demonstrate that the model fits the data [48-51]. The maximum
likelihood method (MLM) was used for parameter estimation.
Model development followed a structured approach. We conducted comprehensive
literature review that informed the development of a causal directed acyclic graph (DAG)
exhibiting the theoretical relationships among potential confounders of the relationship between
NCI and HRQoL. This information was used to identify potential confounders to be included in
the model [52]. ‘Change- in-estimate’ approach was used to determine confounders to be
included in the model. The aim was to derive the most accurate estimates ( as measured by
mean square error) of the relationship between NCI and HRQOL and obtain a parsimonious
model that controls most confounding [52]. Bivariate analysis using independent sample t-tests,
Pearson correlation coefficients, and one-way analysis of variance (ANOVA) was conducted to
investigate the relationship between NCI and candidate confounders and between HRQoL and
candidate confounders. All variables associated with NCI (p = 0.10) and at the same time
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associated with HRQoL (p = 0.10) were retained as potential confounders. A test for
confounding was conducted in two steps. Firstly, the mean difference of the relationship
between HRQoL (physical and mental) and NCI for a reduced model comprising of NCI, age,
gender at birth and race/ethnicity was estimated. Secondly, potential confounders were added
one after the other and the change in the estimate was observed for each variable added. If the
percentage change in the estimate for the reduced model compared to the model with the
added confounder was greater than 10%, we considered the variable as a confounder and
included it in the model, if no it was ignored.

Results
Characteristics of Participants at Enrollment
Of the 1,857 participants with complete data on the outcome variable, 15.6% had severe
comorbidities, 54.0% had incidental comorbidities while 30.0% had contributing comorbidities.
Comorbid conditions included brain trauma, epilepsy, low reading levels, major depression,
lifetime or current substance use or alcohol disorder to name but a few. Severe comorbidities
confound NCI diagnosis so 247 participants with severe comorbidities were excluded from the
study [44]. The final sample (n = 1,340) included 77.2% males, 46.9% Black or African Americans,
41.1% Whites and 70.5% unemployed participants. The mean age was 43.0 years (SD = 8.65).
Approximately one third of the participants were neurocognitively impaired as determined by their
GDS scores (table 2).
Factor Analysis
The results of the exploratory factor analysis confirmed that two factors could be extracted
from the 10 scales of the MOS questionnaire (the scale health transition did not load on any factor
in exploratory factor analysis). The rotated factor pattern was used to determine scales that
loaded on which factor. A scale was said to load on physical health and not on mental health if a
factor loading of the scale was 0.4 or higher on the physical health factor but less than 0.4 on the
mental health factor [48]. Five factors loaded on mental health and five factors loaded on physical
8

health. The factor pattern showed simple structure (i.e., no scale loaded on more than one factor).
A review of the eigenvalues, proportion of variance explained, and the scree plots combined with
the rotated factor pattern demonstrated that the MOS questionnaire can be summarized into two
factors; mental health and physical health.
Means, standard deviations and Pearson correlation coefficients for the 10 scales of the
MOS questionnaire using the full sample were computed (table 1). The Pearson correlation
coefficients ranged from 0.33 to 0.66, indicating a relatively strong positive association among the
variables. The standardized path coefficients for the factor loadings are shown on figure 2. The tvalues for all standardized path coefficients were statistically significant (p < 0.001) and all the
standardized path coefficients were greater than 0.65, providing support for the convergent
validity of the scales [48].
Differences in Clinical Characteristics Between HIV Impaired and Unimpaired Participants.
The Mann Whitney test was conducted to determine whether there are differences between
impaired and unimpaired participants on main clinical variables. Compared to unimpaired
participants, impaired participants had higher median white blood cell count (Z = 2.12 , p = 0.034),
lower hematocrit percentage in blood (Z = -2.10, p = 0.036), lower blood hemoglobin levels (Z =
-2.09, p = 0.037 ), higher mean corpuscular (cell) volume (Z = 3.08, p = 0.002), higher alkaline
phosphatase levels (Z = 2.81, p = 0.005), higher serum triglycerides (Z = 2.19, p = 0.029), higher
white blood cell counts in cerebrospinal fluid (Z = -2.97, p < 0.003), and higher monocyte
percentage in CSF (Z = 3.14, p = 0.001). Nevertheless, the average values were within normal
clinical range for both impaired and unimpaired groups.
Differences in HRQoL Between HIV Neurocognitive Impaired and Unimpaired Participants.
The results of t-tests showed that unimpaired participants had higher physical (p =
0.001) and mental HRQoL composite scores (p < 0.001) than impaired participants, with higher
scores indicating better quality of life perception, less pain or role limitation. Specifically,
unimpaired participants reported higher mean scores for mental health (p = 0.004),
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energy/fatigue (p = 0.006), health distress (p = 0.001), cognitive function (p < 0.001), physical
function (p < 0.001), role function (p = 0.002), and social function (p = 0.009) compared to
impaired participants. However, impaired and unimpaired participants had similar quality of life
perception (p = 0.175), pain (p = 0.164) and general health perception (p = 0.141).
Confounders of the Relationship Between HIV-Associated Neurocognitive Impairment and
HRQoL.
In unadjusted analyses, the following were identified as potential confounders of the
relationship between HIV associated neurocognitive impairment (NCI) and HRQOL at the 5%
level of significance: gender at birth, race/ethnicity, employment, highly active antiretroviral
therapy, lowest CD4 count (cells/mm3), current psychotropic medication use, life time alcohol
abuse or dependence, current opiate test result, high cholesterol, cerebrospinal fluid (CSF)
glucose, CSF total protein, hematocrit percentage (g/dl) in blood, hemoglobin (g/dl) in blood,
mean corpuscular (cell) volume (x10^-15 L (fL)) in blood, basophil percentage in blood and serum
alkaline phosphatase level (IU/L). Age and education where associated with physical but not
mental HRQoL or impairment. The potential confounders that met the criteria for inclusion in the
models for mental and physical HRQoL are shown on tables 2 and 3.
The Relationship Between Impairment and Mental and Physical HRQoL in Adjusted
Analysis.
The relationship between mental health related quality of life (HRQoL) and HIV-associated
NCI as measured by global deficit scores was significant in unadjusted and adjusted analysis.
Impaired participants had lower mental health related quality of life compared to unimpaired
participants. The association between NCI and HRQoL was lower in unadjusted [-4.38 (-6.70 to 2.06)] than in adjusted analysis [-2.56 (-4.83 to -0.30)] and remain significant when controlled for
age, gender at birth, race/ethnicity, unemployment and current psychotropic medication use. In
adjusted analysis, female gender, white and Hispanic race/ethnicity, current unemployment or
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part-time employment and current prescribed psychotropic medication use were associated with
lower mental HRQoL (table 2).
The association between NCI and physical HRQoL was significant in crude analysis [-4.62
(-7.45 to -1.78)] but not significant when adjusted for gender, age, race/ethnicity, employment,
lowest CD4 count (cells/mm3) and positive opiate test results [-2.20 (-4.81 to 0.40)]. In adjusted
analysis, female gender, white race/ethnicity, ages 40 to 59, unemployment, lowest CD4 below
500 cells/mm3 and positive opiate test results were associated with lower physical HRQoL (table
3).
The Durbin-Watson test coefficients for the mental and physical HRQoL models were less
than 2.0 indicating that the residuals were uncorrelated. An analysis of the model residual plots
against predicted values showed no patterns implying homogeneity of variance. The Q-Q plots
showed a linear trend with only minor deviations at the upper tail, satisfying the assumptions of
normality of residuals. Additionally, the variance inflation factors were below 1.2 meaning that
there was no multicollinearity in the model. The predicted values were reasonable, within the
range of the response variable indicating that the models fit the data.
The Mediation Effect of Depression.
Depression was not included in the models because we hypothesized that depression was
a mediator of the relationship between impairment and HRQoL. To test this assumption, we used
the approach in [53] to investigate the extent to which depression mediated the relationship
between HIV neurocognitive impairment (NCI) and HRQoL using ordinary least squares in SAS
version 9.4. To established mediation, NCI (independent variable) must be associated with
depression (mediator), NCI must be associated with HRQoL (dependent variable) and depression
must be associated with HRQoL [53, 55]. We regressed (a) depression on impairment (b) HRQoL
on NCI (c) HRQoL on NCI controlling for depression and (d) depression on HRQoL.
The results of the ordinary least squares regression show that NCI was negatively
associated with depression (B = -1.583, p = 0.020) and depression was negatively associated
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with mental (B = -0.450, p < 0.001) and physical HRQoL (B = -0.261, p < 0.001). Controlling for
depression, neurocognitive impairment was associated with mental (B = 2.048, p = 0.005) and
physical HRQoL ( B = 0.826, p = 0.528) although the relationship for physical health was not
significant. The indirect effect of impairment on mental health (Sobel z = 2.236, p = 0.020) and
physical health (Sobel z = 2.074, p = 0.038) as indicated by the Sobel test was significant. The
proportion of the total effect mediated was higher for physical health (72.2%) than for mental
health (51.5%). These results suggest that depression was a mediator of the relationship between
HIV-associated NCI and mental and physical health related quality of life [53].
There was a significant relationship between depression as measured by the Beck’s
depression index and employment. Among participants with mild to severe depressive
symptomatology, 78.1% were unemployed compared to 10.5% that were fully employed. Mild to
severe depression was regarded as having a score of greater than 13 points on the Beck’s
depression index. In crude analysis, being unemployed increases the odds of mild to severe
depression by 2.83 (1.96 to 4.08) and being employed part-time increases the odds of mild to
severe depression by 1.97 (1.20 to 3.21) compared to being fully employed. However,
employment was not a mediator of the relationship between HIV-associated NCI and HRQoL
(z = 1.603, p = 0.109).
Discussion.
Among HIV-positive CHARTER participants without confounding comorbidities we found
a significant relationship between HIV-associated neurocognitive impairment (NCI) and health
related quality of life (HRQoL). In unadjusted and adjusted analysis, impaired participants had
significantly lower mental HRQoL scores compared to unimpaired participants. The results also
suggest that impaired participants had lower physical HRQoL in crude analysis. The association
between NCI and physical HRQoL remained negative when controlled for employment and other
covariates but was no longer significant.
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Unemployment was a stronger predictor of lower physical and mental HRQoL in this
population than HIV-associated NCI. The strong association of employment with HRQoL may
partly be explained by the association between employment and depression reflected in the
mediation effect of depression on HIV-associated NCI and HRQoL. The beneficial effect of
employment on depression and general mental health is well established. Employment has a
protective effect on depression and general mental health and well-being [56, 57, 59], and
psychological distress [58, 59]. Employment improves quality of life because it provides the
means to acquire the necessities of life, improves consumption of goods and services, enhance
economic and social status, and reduce physical and mental distress arising from worry
associated with economic insecurity.
In adjusted analysis, we also found that prescribed psychotropic drug use was significantly
associated with mental HRQoL but not with physical health. Prescribed psychotropic medication
use is partly induced by psychiatric problems such as depression. Some of the psychotropic drugs
used to ameliorate the harmful health effects of psychiatric problems can affect cognitive function.
Psychotropic drug use negatively affects memory, attention and psychomotor performance and
is associated with lower cognitive scores in the elderly [62] and lower health related quality of life
[60-63].
The results of our study suggest that HRQoL significantly decreases with increasing
severity of depression and depression mediates the relationship between HIV-associated NCI
and HRQoL . This is consistent with findings from several studies that demonstrated that
depression has a deleterious effect on mental health, role, emotional and social functioning of
various patient groups [60, 61], decreases cognitive function [28] and mediates the relationship
between NCI and HRQoL [53].
In both unadjusted and adjusted analysis, opiate use was significantly associated with
lower physical HRQoL but not with mental HRQoL. Participants with positive opiate test results
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had significantly lower physical HRQoL compared to persons with a negative result. The
association between opiate addiction, substance use and alcohol abuse and neurocognitive
functioning are well established. Opiate addiction, chronic substance or alcohol abuse can
aggravate the deleterious effect of HIV on brain metabolites and can lead to neuronal injury,
affects neuropsychological functioning, alter health behavior and results in low levels of
medication adherence [13- 15, 37, 64].
With 30 million people projected to be on combination antiretroviral therapy (cART) by
2020 (UNAIDS, 2016), and given the observed increase in life expectancy of HIV seropositive
individuals on cART, the potential collective impact of HIV-associated NCI, depression, substance
abuse, psychotropic medication use and unemployment on a large proportion of these population
should be of serious concern. This is particularly important because HIV and age-related cognitive
impairment, substance abuse and depression affect the individual’s ability to adhere to
medication, perform activities of daily living, hold, or maintain a job, and live a normal productive
life. HIV seropositive persons on cART are living longer implying that HIV is becoming a chronic
disease, requiring continuous management. The combined effect of neurocognitive deficits,
substance abuse, unemployment and depression are likely to contribute significantly to decline in
HRQoL with significant impact on healthy aging. There is need to design specific interventions
aimed at the optimal management and improvement in the quality of life of persons living with
HIV, including the management of depression and maintenance of employment.
In this study, HRQoL was conceptualized within the framework of the Medical Outcome
Survey (MOS) questionnaire which measures HRQoL using 35 items that require individuals to
provide a subjective evaluation of their health and wellbeing. The questionnaire was designed to
measure11 scales of HRQoL (mental health, energy or fatigue, health distress, cognitive function,
quality of life, pain, physical functioning, role functioning, social functioning, general health and
health transition). Consistent with our secondary objectives and in harmony with previous
research findings in [47], we established using factor analysis that the 35-item MOS questionnaire
14

can be summarized into two dimensions, physical and mental HRQoL and is a reliable and valid
measure of HRQoL.
Limitations
The study has some limitations. First the CHARTER study was based on a volunteer
sample comprising of individuals attending clinics in the study centers. This implies that the
sample is not representative of HIV-patients in other clinics or patients who would not volunteer
for such studies (see https://neuroaids-dcc.unmc.edu/CharterResDesc). To address this concern,
and to ensure that the CHARTER sample was as inclusive as possible of the population of HIV
participants visiting the study clinics, minimal exclusion criteria was used. Participants were
recruited from six sites widely distributed within the United States.
Data was collected using mix methods involving patient self-reports for outcome variable,
and a mixture of clinician ratings and self- report for the exposure variable. This implies that the
data is subject to mode effects. The relationship between neurocognitive impairment and quality
of life is influenced by a mesh of factors, which confound , mediate or moderate the relationship.
This may be a source of bias. To limit the impact of confounding on the analysis, structured
approach to bias was applied by analyzing the various causal pathways of the relationship
between the two variables. The directed acyclic graph (DAG) approach was used to identify the
most important confounders and statistical tests were conducted with these variables to determine
confounding effects.
Conclusion
We used baseline data from the prospective, observational CHARTER study to investigate
the relationship between HIV-associated NCI, as measured by GDS, and HRQoL. We
hypothesized that NCI is associated with lower physical and mental HRQoL and that NCI
participants have lower HRQoL than unimpaired HIV participants in the CHARTER study. Our
central hypothesis was supported in unadjusted and adjusted analysis for mental health, but the
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inverse relationship between HIV associated neurocognitive impairment and physical HRQoL was
no longer significant when adjusted for other covariates. Depression is a strong mediator of the
relationship between HIV associated neurocognitive impairment and HRQoL. The implication of
the mediation effect of depression is that in the CHARTER population, managing depression
should be a potential target to lessen the risk of HIV neurocognitive impairment and improve
HRQoL.
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Figure1
Flow chart showing final sample sizes

2,016 participants were screened for
the CHARTER study
366 elected not to
participate.

40 not asked to
continue or did not
meet criteria to
continue.
1,610 participated in cross sectional
study.
23 Missing data on
outcome variable.
1,587 complete cases on outcome
variable used in factor analysis for this
study.

247 excluded from analysis
due to confounding
comorbidities
1,340 cases without confounding
comorbidities used for analysis.
34 cases missing data
on physical health
confounding variables

275 cases missing data on
mental health confounding
variables

1,306 complete case
analysis on physical
health for final model.

1065 complete case
analysis on mental health
for final model.

17

Figure 2:
Path model of health-related quality of life of CHARTER participants (n = 1,587)
Cognitive Function
V4

0.718*
Quality of Life
V5

Health Distress
V3

0.789*

Energy/ Fatigue
V2

0.798*

0.677*
Mental Health
Mental Health
F1

0.806*

V1

0.848

Physical Health
F2

0.771*
Pain
V6

General Health
V10

0.736*
0.717*
Physical Function
V7

0.708*

Role Function
V8

0.776*
Social Function
V9

Single headed arrows show standardized path coefficients; Curved double headed arrow shows
covariance for two factors. * p < 0.001. F1, Factor 1; F2, Factor 2; V1…V10, represents variable name.
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Table 1
Means, standard deviations and Pearson correlation coefficients for the health-related quality of
life (HRQoL) scales of the medical outcome survey questionnaire (n=1,587).
No
1
2
3
4
5
6
7
8
9
10

Scales
Mean SD
Mental health
66.55 21.66
Energy/Fatigue 53.28 22.21
Health distress 72.10 26.33
Cognitive
72.13 23.80
function
Quality of life
64.44 22.06
Pain
66.24 26.73
Physical
69.02 27.47
function
Role function
54.09 45.32
Social function
74.12 28.45
General health 48.25 26.91

1
1
.66
.66
.59

2

3

4

5

6

7

1
.57
.56

1
.59

1

.59
.42
.35

.55
.52
.49

.50
.50
.45

.43
.41
.43

1
.42
.33

1
.58

1

.38
.53
.52

.49
.56
.59

.47
.60
.60

.41
.54
.46

.36
.44
.56

.51
.55
.58

.55
.58
.52

8

1
.56
.56

Note: Higher mean scores indicate better quality of life perception, lower pain and limitations in role
function; the scale health transition did not load on any factor.
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9 10

1
.54

1

Table 2
The relationship between neurocognitive impairment and mental-related quality of life (HRQoL) of CHARTER
participants
(n = 1,065).
Mental HRQoL
Unadjusted mean
Adjusted mean
composite
difference
differencec
scores
c
Variable
n (%)
(95% CI)
(95% CI)
Mean (SD)a

Neurocognitive impairment (GDS)d
No
679 (63.8)
Yes
386 (36.2)
Gender at Birth
Male
807 (75.8)
Female
258 (24.2)
Age (years)
≤ 39
321 (30.2)
40-49
504 (47.3)
50-59
212 (19.9)
≥ 60
28 (2.6)
Race/Ethnicity
Black or African
479 (45.0)
American
White
462 (43.4)
Hispanic
99 (9.3)
Other
25 (2.3)
Employment
Full time
152 (14.2)
Part-time
137 (12.9)
Not currently employed
776 (72.9)
Current psychotropic medication use
No
310 (29.1)
Yes
755 (70.9)

65.82 (18.82)
61.45 (18.11)

p < 0.002
ref
-4.38 (-6.70 to -2.06)

ref
-2.56 (-4.83 to -0.30)

p = 0.273
64.59 (18.35)
63.12 (19.66)

-1.47 (-4.09 to 1.15)

-2.14 (-4.75 to 0.46)

p = 0.571
64.87 (19.08)
64.05 (18.38)
63.24 (18.35)
67.74 (21.84)

ref
-0.82 (-3.44 to 1.80)
-1.63 (-4.88 to 1.61)
2.86 (-4.36 to 10.09)
p = 0.001

ref
-0.11 (-2.65 to 2.42)
-0.09 (-3.22 to 3.04)
4.23 (-2.68 to 11.14)

ref
-4.69 (-7.07 to -2.32)
-4.17 (-8.19 to -0.15)
-3.66 (-11.13 to 3.81)

ref
-5.86 (-8.28 to -3.44)
-4.17 (-8.09 to -0.25)
-5.05 (-12.25 to 2.15)

66.75 (18.07)
62.05 (18.97)
62.58 (17.56)
63.09 (23.76)

p < 0.001
71.96 (16.53)
65.50 (18.57)
62.50 (18.71)

ref
-6.46 (-10.71 to -2.20)
-9.46 (-12.66 to -6.26)

ref
-6.64 (-10.78 to -2.50)
-8.96 (-12.17 to -5.75)

p < 0.001
71.28 (16.21)
61.34 (18.86)

ref
-9.93 (-12.33 to -7.53)

ref
-8.21 (-10.63 to -5.80)

n = sample size with percentage of respondents in bracket; ref means the reference category. aSD, Standard deviation, bCI, Confidence
interval. cAdjusted for other covariates in the table using general linear model analysis.; eGDS, global deficit scores, were used to
determine impairment.
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Table 3
The relationship between HIV associated neurocognitive impairment and physical health-related quality of life (HRQoL)
of CHARTER participants (n = 1,306).
Physical HRQoL
Unadjusted mean
Adjusted mean
Variable
n (%)
composite scores
difference
differenceb
c
a
Mean (SD)
(95% CI)
(95% CI)
Neurocognitive impairment
p = 0.001
(GDS)e
843 (64.5)
65.17 (25.04)
No
ref
ref
463 (35.5)
60.55 (24.92)
-4.62 (-7.45 to -1.78)
-2.20 (-4.81 to 0.40)
Yes
Gender at Birth

p < 0.001
ref

1,008 (77.2)

65.00 (24.96)

298 (22.8)

58.55 (24.92)

-6.45 (-9.67 to -3.22)
p < 0.001

≤ 39

422 (32.3)

70.60 (23.83)

40-49

594 (45.5)

61.42 (24.65)

ref
-9.19 (-12.25 to -6.12)

ref
-6.32 (-4.28 to -9.21)

50-59

254 (19.4)

56.43 (24.96)

-14.17 (-18.00 to -10.35)

-10.49 (-14.-8 to -6.91)

36 (2.8)

65.50 (28.10)

-5.11 (-13.47 to 3.26)

-2.36 (-10.10 to 5.38)

605 (46.3)

62.79 (23.98)

544 (41.7)
124 (9.5)
33 (2.5)

Male
Female
Age (years)

≥ 60
Race/Ethnicity
Black or African
American
White
Hispanic
Other

p = 0.606
ref

ref

63.69 (26.23)

0.90 (-2.01 to 3.81)

-4.45 (-7.22 to -1.68)

65.69 (24.30)

2.95 (-1.96 to 7.75)

0.51 (-3.93 to 4.96)

66.22 (28.76)

3.42 (-5.38 to 12.23)

-3.21 (-11.21 to 4.79)

Employmente
Full time
Part-time
Not currently
employed
Lowest CD4 count (cells/mm 3)
≥ 500

ref
-6.53 (-9.57 to -3.49)

p < 0.001
222 (17.0)

82.31 (17.45)

163 (12.5)

68.66 (21.23)

ref
-13.65 (-18.38 to -8.92)

ref
-11.95 (-16.58 to -7.33)

921 (70.5)

58.09 (24.91)

-24.22 (-27.65 to -20.79)

-21.97 (-25.44 to -18.50)

p < 0.001
121 (9.3)

72.77 (24.49)

200-499

481 (36.8)

65.74 (25.84)

ref
-12.34 (-17.13 to -7.55)

ref
-6.08 (-10.60 to -1.56)

< 200

704 (53.9)

60.43 (24.13)

-7.04 (-12.00 to -2.09)

-7.20 (-11.64 to -2.77)

Current opiate test results
Positive
Negative

p < 0.001
95 (7.3)

48.61 (24.92)

1,211 (92.7)

64.70 (24.73)

ref
16.09 (10.91 to 21.26)

ref
11.12 (6.35 to 15.90)

n = sample size with percentage of respondents in bracket; ref means the reference category. aSD, Standard deviation, bCI, Confidence
interval. cAdjusted for other covariates in the table using general linear model analysis. eGDS, global deficit scores, were used to
determine impairment.
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Supplementary Tables

Table 4: CHARTERa study neuropsychological test battery by cognitive domain.
Domain

Test

1. Speed of Information

Wechsler Adult Intelligence Scale [WAIS]-II Digit Symbol

Processing

WAIS-III -Symbol Search
Trail Making Test Part A

2. Learning

Hopkins Verbal Learning Tests Revised [HVLT-R] Learning Trials
Brief Visuospatial Memory Test Revised [BVMT-R]
Learning Trials
Story Memory Test (Learning Component);
Figure Memory Test (Learning Component)

3. Memory

HVLT-R Delayed Recall, BVMT-R Delayed Recall,
Story Memory Test (with delayed recall),
Figure Memory Test (delayed recall component);
Brief Visuospatial Memory Test Revised,
Category Fluency Test,

4. Executive Function

Wisconsin Card Sorting Computerized Test [64-item version],
Trail Making Test Part B

5. Verbal Fluency

Verbal Fluency-Controlled Oral Word Association Test [F-A-S
letters]
Category Fluency Test [animals]

6.

Attention

and

Working

Paced Auditory Serial Addition Test-50

Memory

WAIS-III Letter-Number Sequencing

7. Motor Function

Grooved Pegboard Test, Dominant and Non-Dominant Hands.

aCHARTER,

Central nervous system HIV antiretroviral therapy effects research
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Table 5 Differences in health-related quality of life (HRQoL) between HIV neurocognitive
impaired and unimpaired CHARTER participants.
Impaired (n = 477)

Unimpaired (n = 863)

Mean (SD)

Mean (SD)

Mental
Mental health
Energy/Fatigue
Health distress
Cognitive function
Quality of life

64.9 (21.5)
51.4 (22.6)
70.8 (25.6)
69.4 (24.1)
63.5 (22.2)

68.4 (21.2)
54.9 (22.0)
75.0 (25.5)
75.9 (22.1)
65.2 (21.5)

.004
.006
.004
< .001
.175

Mental compositeb

64.0 (18.4)

67.9 (18.6)

< .001

65.6 (27.6)
65.5 (27.8)
50.4 (45.6)
72.3 (28.5)
47.9 (25.7)

67.7 (26.0)
72.7 (26.7)
58.3 (45.0)
76.5 (27.4)
50.2 (27.7)

.164
<.001
.002
.009
.141

60.3 (24.7)

65.1 (25.9)

.001

Scales

Physical
Pain
Physical function
Role function
Social function
General health
Physical composite
ap-value

p-valuea

based on t-test, p-value > 0.05 means not significant, SD, Standard deviation, CHARTER means , Central nervous system (CNS) HIV
antiretroviral therapy effects research study. bMental and physical health-related quality of life composite scores were computed as factorbased scores by adding the average HRQoL scores on all preceding scales that loaded on same factor during the factor analysis
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